Clinical Trial Update: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating LY3540378 in participants with worsening heart failure with preserved ejection fraction was terminated, and the results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LY3540378 (LY3540378)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: TERMINATED | Results posted: 2026-02-05